First-in-Human Safety, Tolerability, and Pharmacokinetics of Single-Dose Kukoamine B Mesylate in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase I Study

被引：0
作者：
Hongzhong Liu
Qian Zhao
Yuping Yuan
Zhenlei Wang
Teng Wang
Wei Tian
Wen Zhong
Ji Jiang
Shuai Chen
Kai Kong
Chunyan Jin
Pei Hu
机构：
[1] Peking Union Medical College Hospital,Clinical Pharmacology Research Center, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK and PD Investigat
[2] Chinese Academy of Medical Sciences & Peking Union Medical College,Clinical Research Center for Innovative Drugs
[3] Tianjin Chasesun Pharmaceutical Co.,undefined
[4] Ltd.,undefined
来源：
Infectious Diseases and Therapy | 2024年 / 13卷
关键词：
Kukoamine B; Phase I trial; Pharmacokinetic; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：361 / 371
页数：10
相关论文
共 50 条
  • [21] Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study
    Risinger, Robert
    Bhagwagar, Zubin
    Luo, Feng
    Cahir, Matthew
    Miler, Laura
    Mendonza, Anisha E.
    Meyer, Jeffrey H.
    Zheng, Ming
    Hayes, Wendy
    PSYCHOPHARMACOLOGY, 2014, 231 (11) : 2299 - 2310
  • [22] Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study
    Robert Risinger
    Zubin Bhagwagar
    Feng Luo
    Matthew Cahir
    Laura Miler
    Anisha E. Mendonza
    Jeffrey H. Meyer
    Ming Zheng
    Wendy Hayes
    Psychopharmacology, 2014, 231 : 2299 - 2310
  • [23] Safety, tolerability and pharmacokinetics of forsythin in healthy subjects: a double-blinded, placebo-controlled single-dose and multiple-dose escalation and food effect study
    Li, Cuiyun
    Wu, Min
    Zhang, Hong
    Zhu, Xiaoxue
    Fu, Li
    Wang, Shuo
    Lu, Mingming
    Zhong, Dafang
    Ding, Yanhua
    ANNALS OF MEDICINE, 2023, 55 (02)
  • [24] A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants
    Li, Yunfei
    Zhang, Hua
    Pandya, Hitesh
    Miao, Liyan
    Reid, Fred
    Jimenez, Eulalia
    Sadiq, Muhammad Waqas
    Moate, Rachel
    Lei, Alejhandra
    Zhou, Xiao-Hong
    Kell, Chris
    Ding, Junjie
    Zhang, Guanlin
    Zhao, Lina
    Ge, Xiaoyun
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (06): : 665 - 671
  • [25] A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects
    Vladimir Hanes
    Vincent Chow
    Tina Stewart
    Adeep Puri
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 879 - 886
  • [26] A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects
    Hanes, Vladimir
    Chow, Vincent
    Stewart, Tina
    Puri, Adeep
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (05) : 879 - 886
  • [27] Safety, tolerability, pharmacokinetics and neutrophil elastase inhibitory effects of Sivelestat: A randomized, double-blind, placebo-controlled singleand multiple-dose escalation study in Chinese healthy subjects
    Li, Kun
    Dong, Lingfang
    Gao, Shan
    Zhang, Jingying
    Feng, Yinghua
    Gu, Li
    Yang, Jie
    Liu, Xing
    Wang, Yaqin
    Mao, Zhenkun
    Jiang, Dandan
    Xia, Zhengchao
    Zhang, Guoliang
    Tang, Jingwen
    Ma, Peizhi
    Zhang, Wei
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 195
  • [28] Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study
    Zhu, Xiaoxue
    Wu, Min
    Wang, Hong
    Li, Haijun
    Lin, Junjie
    Peng, Yun
    Hu, Yue
    Li, Cuiyun
    Ding, Yanhua
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (05) : 579 - 589
  • [29] Methylphenidate, cognition, and epilepsy A double-blind, placebo-controlled, single-dose study
    Adams, Jesse
    Alipio-Jocson, Valerie
    Inoyama, Katherine
    Bartlett, Victoria
    Sandhu, Saira
    Oso, Jemima
    Barry, John J.
    Loring, David W.
    Meador, Kimford
    NEUROLOGY, 2017, 88 (05) : 470 - 476
  • [30] Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects
    Sun, Cheng
    Liu, Hao
    Ouyang, Ziwei
    Ding, Jie
    Zhang, Qin
    Ma, Hongjie
    Xu, Dandan
    Zhang, Qian
    Zhou, Renpeng
    Yang, Mingming
    Hu, Wei
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (05) : 533 - 542
12345